Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.

Sandoz Group AG

Novartis

Sandoz do Brasil

Sandoz Egypt

Sandoz Italia

Sandoz in Deutschland

Lek Pharmaceuticals

Sandoz India Pvt Ltd

Sandoz México

Sandoz Canada

Sandoz France

Sandoz Polska

Life at Sandoz

Sandoz Czech Republic

Sandoz Srbija

Sandoz Romania

Sandoz Hrvatska

Sandoz Nederland

Sandoz UK

Sandoz Australia & New Zealand

Sandoz Hungária

Sandoz Danmark

Sandoz Sverige

Sandoz is the global leader in generic and biosimilar medicines. 

Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance.

 We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars.

Sandoz

Today officially marks the start of a new era for Sandoz - a now independent, global leader in generic and biosimilar medicines.

We know that access to generic and biosimilar medicines allows healthcare systems across the globe to deliver high-quality, affordable treatments to people facing some of the most challenging diseases.

Off-patent therapies account for 80% of medicines used worldwide, a statistic that underscores why our Purpose, pioneering access for patients, is so important.

We believe that the world needs affordable, sustainable and high-quality healthcare now more than ever - and we will deliver on our purpose with renewed focus and ambition, working always with patients in mind.

Find out how we're shaping the future of healthcare: www.sandoz.com

#NewSandoz #Biosimilars #PioneeringAccess

Two months since becoming an independently listed medicines company and the energy is still high!

Every associate has contributed to this incredible moment and now we are well on our way to shaping our own future and bringing affordable medicines to millions.

Join Naoki Ito and our colleagues across the world in making an impact on human health: https://lnkd.in/eTcSpcQR
 
#SandozLife #Sandoz #PharmaJobs

We’ve wrapped up another successful Sandoz Research & Development (SRDD) days! 🙌

We spent the past three days recognizing the hard work of our employees, as well as their scientific achievements, which enable Sandoz to achieve its purpose of pioneering access to life-changing medicines for patients.

R&D days is all about sharing best practices, networking, learning from each other, and celebrating together. This is one of the ways we are creating a best-in-class experience for our employees as part of our commitment to accelerate their professional growth. To find out more about our supportive culture and our opportunities – visit our careers page: https://lnkd.in/eAJa7x8W

#SandozLife #CompanyCulture #WorkplaceCulture

Biosimilars have been available in Japan since 2009. So, why does biosimilar uptake lag behind other key markets globally and what can we learn from Europe's mature and well-developed biosimilar industry to improve the situation in Japan?🌎

Last week, we sponsored a panel discussion with Nikkei Business Publications, where Peter Stenico, Global Head Biosimilars and Country President Austria, joined leading Japanese public health and policy experts to discuss solutions for increased biosimilar adoption in Japan.

The discussions yielded useful insights into what has helped drive successful biosimilar adoption in Europe to date. Continuing to review and adopt approaches and policies that have contributed to strong uptake in other markets will be vital in supporting expanded access to biosimilars in Japan in the future.

We remain committed to driving conversations that support increased awareness about the potential and global uptake of biosimilars, so that patients and healthcare systems across the world can access these potentially life-changing medicines.💊

A huge thanks to everyone who contributed to this engaging discussion and to those who joined to watch live!

#PioneeringAccess #Biosimilars

Success in generics and biosimilars is not just about developing and manufacturing affordable, high-quality medicines. It’s essential to understand patient needs and perspectives. That’s why we involve the perspectives of the patient community in our work at Sandoz to pioneer access for patients.

Last week, our Global Director, Patient Communications and Engagement Izlen Toker spoke at the Patient Engagement Conference in Amsterdam about authentic patient advocacy and Sandoz’ approach to patient engagement.

Follow us to learn more about our commitment to working with patients in mind.
 
#PatientAdvocacy #WithPatientsInMind #Sandoz

Martin Schiestl, Global Head Regulatory Affairs Policy at Sandoz, has been recognized within the Contribution category at this year’s TOPRA - The Organisation for Professionals in Regulatory Affairs Awards for Regulatory Excellence! 🏆

This prestigious award highlights regulatory affairs professionals who have consistently demonstrated exceptional dedication and expertise over the past three years.

Martin's achievements are truly remarkable, reflecting a high level of regulatory affairs expertise, a commitment to driving more consistent patient access to medicines, and the ambition to identify biosimilar regulatory pathways. With almost three decades of experience, his role as a mentor to colleagues, coupled with his commitment to the improvement of regulatory affairs, is inspiring. Congratulations Martin for this well-deserved win! 🌟

#RegAwards23 #RegulatoryExcellence

As the global leader in off-patent medicines, we contribute to keeping healthcare systems sustainable and ensuring patients can afford the treatment they need, where and when they need it.

Access to care is one of our biggest concerns as a company. We work tirelessly to ensure high-quality treatments are readily available not only to patients, but also healthcare systems, globally.

Read more about how we continue to pioneer access: https://lnkd.in/eYvdw5rM

#PioneeringAccess #HealthEquity #Biosimilars

At Sandoz, diversity, equity and inclusion are at the heart of all we do.

We pride ourselves in ensuring our colleagues feel valued, respected and heard - so that everyone can be their authentic selves!

Click to learn more: https://lnkd.in/en3jcUGj

#SandozLife #WorkplaceCulture #CompanyCulture #Careers

Biosimilars allow patients worldwide to enjoy a better quality of life. Join #GlobalBiosimilarsWeek to get an insight into the opportunities biosimilar medicines can provide: https://lnkd.in/ewKrhd6z

We believe that being the global leader in generic and biosimilar medicines comes with an added layer of responsibility around manufacturing, access and use of antibiotics.

We want to make a positive change for both healthcare systems and patients globally - and our work against antimicrobial resistance shows just this: 
👉We produce 50+ medicines in generic antibiotics serving more than 200 million patients per year
👉We have a leading global program to combat AMR, taking a balanced, cross-sector approach

Our goal is simple: we want to ensure patients continue to receive the medicine they need, when and where they need it. Learn more about how we aim to achieve it: https://lnkd.in/eYvdw5rM

#AMR #AntimicrobialResistance #Biosimilars

	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24
net income	217.15M -	224.34M 3.31%	186.48M 16.87%	174.75M 6.29%	107.49M 38.49%	105.16M 2.16%	-72.32M 168.77%	-66.45M 8.12%	75M 212.87%	75M 0%
depreciation and amortization	110.42M -	114.08M 3.31%	108.04M 5.29%	101.24M 6.29%	115.26M 13.85%	112.77M 2.16%	98.86M 12.33%	90.84M 8.12%	120M 32.11%	120M 0%
deferred income tax
stock based compensation			32.56M -	30.51M 6.29%			37.99M -	34.90M 8.12%
change in working capital	-188.97M -	-195.22M 3.31%	119.39M 161.16%	111.88M 6.29%	-310.11M 377.19%	-303.41M 2.16%	-225.64M 25.63%	-207.33M 8.12%	-113M 45.50%	-113M 0%
accounts receivables	-98.87M -	-102.14M 3.31%	14.80M 114.49%	13.87M 6.29%	-64.95M 568.31%	-63.55M 2.16%	-114.88M 80.79%	-105.56M 8.12%	-45M 57.37%	-45M 0%
inventory	-110.42M -	-114.08M 3.31%	-16.28M 85.73%	-15.26M 6.29%	-204.45M 1,240.17%	-200.03M 2.16%	-59.96M 70.03%	-55.09M 8.12%	-136.50M 147.77%	-136.50M 0%
accounts payables
other working capital	20.33M -	21.00M 3.31%	120.87M 475.52%	113.26M 6.29%	-40.71M 135.94%	-39.83M 2.16%	-50.80M 27.56%	-46.68M 8.12%	68.50M 246.74%	68.50M 0%
other non cash items	19.41M -	20.05M 3.31%	-11.84M 159.06%	-11.10M 6.29%	126.24M 1,237.80%	123.51M 2.16%	287.89M 133.09%	264.52M 8.12%	32.50M 87.71%	32.50M 0%
net cash provided by operating activities	158.01M -	163.24M 3.31%	434.64M 166.26%	407.28M 6.29%	38.88M 90.45%	38.04M 2.16%	126.78M 233.30%	116.49M 8.12%	114.50M 1.71%	114.50M 0%
investments in property plant and equipment	-57.75M -	-59.66M 3.31%	-75.48M 26.51%	-70.73M 6.29%	-70.90M 0.23%	-69.36M 2.16%	-95.66M 37.91%	-87.89M 8.12%	-82.50M 6.14%	-82.50M 0%
acquisitions net	-14.78M -	-15.27M 3.31%			-7.32M -	-7.16M 2.16%			-94M -	-94M 0%
purchases of investments
sales maturities of investments
other investing activites	-8.32M -	-8.59M 3.31%	-50.32M 485.70%	-47.15M 6.29%	-7.32M 84.48%	-7.16M 2.16%	-99.78M 1,293.53%	-91.68M 8.12%	-20.50M 77.64%	-20.50M 0%
net cash used for investing activites	-80.85M -	-83.53M 3.31%	-125.80M 50.61%	-117.89M 6.29%	-85.53M 27.44%	-83.68M 2.16%	-195.44M 133.54%	-179.57M 8.12%	-197M 9.71%	-197M 0%
debt repayment
common stock issued
common stock repurchased									-6M -	-6M 0%
dividends paid									-107.50M -	-107.50M 0%
other financing activites	-70.23M -	-72.55M 3.31%	-304.39M 319.56%	-285.24M 6.29%	74.10M 125.98%	72.50M 2.16%	494.31M 581.85%	454.18M 8.12%	-500K 100.11%	-500K 0%
net cash used provided by financing activities	-70.23M -	-72.55M 3.31%	-304.39M 319.56%	-285.24M 6.29%	74.10M 125.98%	72.50M 2.16%	494.31M 581.85%	454.18M 8.12%	-114M 125.10%	-114M 0%
effect of forex changes on cash	7.39M -	7.64M 3.31%	-2.96M 138.76%	-2.77M 6.29%	-3.20M 15.43%	-3.13M 2.16%	23.80M 859.77%	21.87M 8.12%	-7.50M 134.30%	-7.50M 0%
net change in cash	14.32M -	14.80M 3.31%	1.48M 90.00%	1.39M 6.29%	24.24M 1,647.92%	23.72M 2.16%	449.46M 1,795.02%	412.97M 8.12%	-204M 149.40%	-204M 0%
cash at beginning of period		52.98M -	67.78M 27.93%
cash at end of period	14.32M -	67.78M 373.22%	69.26M 2.18%	1.39M 98.00%	24.24M 1,647.92%	23.72M 2.16%	449.46M 1,795.02%	412.97M 8.12%	-204M 149.40%	-204M 0%
operating cash flow	158.01M -	163.24M 3.31%	434.64M 166.26%	407.28M 6.29%	38.88M 90.45%	38.04M 2.16%	126.78M 233.30%	116.49M 8.12%	114.50M 1.71%	114.50M 0%
capital expenditure	-57.75M -	-59.66M 3.31%	-75.48M 26.51%	-70.73M 6.29%	-70.90M 0.23%	-69.36M 2.16%	-95.66M 37.91%	-87.89M 8.12%	-82.50M 6.14%	-82.50M 0%
free cash flow	100.26M -	103.58M 3.31%	359.16M 246.75%	336.55M 6.29%	-32.02M 109.51%	-31.33M 2.16%	31.12M 199.35%	28.60M 8.12%	32M 11.90%	32M 0%

SDZ

COM:SANDOZ

Sandoz Group AG

Last Close

40.60

25/11 09:25

Market Cap

15.04B

Beta: -

Volume Today

91.56K

Avg: -

Preview